Breaking Finance News

OncoMed Pharma (NASDAQ:OMED) price target upped to $20.00, released a report earlier today by H.C. Wainwright

Just yesterday OncoMed Pharma (NASDAQ:OMED) traded 2.24% higher at $11.87. OncoMed Pharma’s 50-day moving average is $11.08 and its 200-day moving average is $11.66. The last closing price is up 1.81% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 126,590 shares of OMED traded hands, down from an average trading volume of 208,331

OncoMed Pharma (NASDAQ:OMED) had its price target upped to $20.00 by H.C. Wainwright in an issued report announced 9/22/2016. The bumped up target suggests a potential upside of 0.68% based on the company's last stock close price.

Previously on Tuesday April 12, 2016, BMO Capital Markets reported on OncoMed Pharma (NASDAQ:OMED) increased the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 0.92%.

Recent Performance Chart

OncoMed Pharma (NASDAQ:OMED)

OncoMed Pharma has 52 week low of $8.42 and a 52 week high of $23.98 and has a market capitalization of $0.

A total of 6 analysts have released a research note on OncoMed Pharma. Two analysts rating the company a strong buy, three analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $18.17.

More About OncoMed Pharma (NASDAQ:OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company's Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.